NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/10/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization10,489 mln
Float91.07 mln
Earnings Date10/29/2026
Piotroski F-Score
1
/ 9
Very weak
Beneish M-Score
-0.53
Highly suspicious
1-Year Forecast
110
Exceptional upside
Relative Strength
22
/ 100
Significantly lagging
Debt / Equity
-7.32
Negative equity
Pre-Tax Margin
-1,321%
Severely loss-making
Business Description
Cytokinetics is a US-based drug development company focused on creating medicines that target muscle function to treat serious heart and muscle diseases. Its lead product, MYQORZO, is an approved oral treatment for a condition where the heart muscle becomes abnormally thick and obstructed, and the company has several other drugs in various stages of clinical testing that aim to address different forms of heart failure. Founded in 1997 and based in South San Francisco, Cytokinetics is working to build a portfolio of treatments for patients with few existing options.
